课件：CVA白三稀在咳嗽中的应用解读.ppt

Slide 12: Central Role of Cysteinyl Leukotrienes in Asthma First identified in the late 1970s, the CysLTs, including LTD4, are key mediators in asthma. Early evidence of the importance of LTs in asthma was provided by their recovery in the blood, bronchoalveolar lavage fluid, and urine of patients after spontaneous or induced bronchospasm. The ability of specific LT receptor antagonists to increase airflow and reduce symptoms further supports LT involvement in this disease.1 CysLTs, including LTD4, are generated by inflammatory cells such as mast cells and eosinophils. Through multiple mechanisms, CysLTs and LT receptor occupation have been correlated with1: Increased vascular permeability and edema formation Increased mucus production with decreased mucociliary transport Recruitment of inflammatory cells, such as eosinophils, from bloodstream to airway. Eosinophil influx is a component in the inflammatory process that underlies asthma Eosinophils in the airway releasing inflammatory mediators, including cationic proteins, that can damage the epithelium. Epithelial damage can then expose sensory fibers to allow stimulation of cough or other bronchial reflexes Continued… 知道了治疗的关键是控制慢性炎症，也了解到白三烯在慢性炎症中充当着重要的角色，这就给我们选择治疗的药物体提供了依据。 治疗要达到抗炎和解痉的作用 Slide 31: Montelukast Indications and Important Imformation Montelukast is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years and older. Montelukast should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available. Use of montelukast may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician. Safety and effectiveness of montelukast in patients younger than 2 years have not been established. * 白三烯受体拮抗剂 在咳嗽变异性哮喘中的应用